A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.

被引：1

作者：

Armand, Philippe

Shipp, Margaret Ann

Kuruvilla, John

Collins, Graham P.

Ramchandren, Rod

Timmerman, John

Sumbul, Anne

Ruisi, Mary M.

Kato, Kazunobu

Ansell, Stephen Maxted

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

[4] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[6] Bristol Myers Squibb, Princeton, NJ USA

[7] Mayo Clin, Div Hematol, Rochester, MN USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS7573

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7573

引用

页数：2